Omeros Shares Surge on FDA Approval For Yartemlea

Dow Jones

2025/12/25

By Elias Schisgall

Shares of Omeros surged after the pharmaceutical company received Food and Drug Administration approval for its Yartemlea treatment.

The stock was up 78% to $15.60 on Wednesday and was briefly paused for volatility. Shares have risen 56% this year.

The Seattle-based pharmaceutical company said Wednesday that the FDA greenlit Yartemlea for patients ages 2 and older who experience a serious complication from stem-cell transplant procedures.

The FDA approval makes Yartemlea the only approved treatment that works by inhibiting the effector enzyme of the lectin pathway, Omeros said. It said it is finalizing preparations for a product launch in the U.S. next month.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

December 24, 2025 11:55 ET (16:55 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2594940514"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2594940514\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2594940514?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-25 00:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2594940514","market":"us","top_or_hot":-1,"title":"Omeros Shares Surge on FDA Approval For Yartemlea","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Omeros surged after the pharmaceutical company received Food and Drug Administration approval for its Yartemlea treatment. \n</p>\n<p>\n  The stock was up 78% to $15.60 on Wednesday and was briefly paused for volatility. Shares have risen 56% this year. \n</p>\n<p>\n  The Seattle-based pharmaceutical company said Wednesday that the FDA greenlit Yartemlea for patients ages 2 and older who experience a serious complication from stem-cell transplant procedures. \n</p>\n<p>\n  The FDA approval makes Yartemlea the only approved treatment that works by inhibiting the effector enzyme of the lectin pathway, Omeros said. It said it is finalizing preparations for a product launch in the U.S. next month. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 24, 2025 11:55 ET (16:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Omeros Shares Surge on FDA Approval For Yartemlea</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOmeros Shares Surge on FDA Approval For Yartemlea\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-25 00:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Omeros surged after the pharmaceutical company received Food and Drug Administration approval for its Yartemlea treatment. \n</p>\n<p>\n  The stock was up 78% to $15.60 on Wednesday and was briefly paused for volatility. Shares have risen 56% this year. \n</p>\n<p>\n  The Seattle-based pharmaceutical company said Wednesday that the FDA greenlit Yartemlea for patients ages 2 and older who experience a serious complication from stem-cell transplant procedures. \n</p>\n<p>\n  The FDA approval makes Yartemlea the only approved treatment that works by inhibiting the effector enzyme of the lectin pathway, Omeros said. It said it is finalizing preparations for a product launch in the U.S. next month. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 24, 2025 11:55 ET (16:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2594940514","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2594940514","pubTimestamp":1766595300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Omeros surged after the pharmaceutical company received Food and Drug Administration approval for its Yartemlea treatment.The stock was up 78% to $15.60 on Wednesday and was briefly paused for volatility. Shares have risen 56% this year.The Seattle-based pharmaceutical company said Wednesday that the FDA greenlit Yartemlea for patients ages 2 and older who experience a serious complication from stem-cell transplant procedures.The FDA approval makes Yartemlea the only approved treatment that works by inhibiting the effector enzyme of the lectin pathway, Omeros said. It said it is finalizing preparations for a product launch in the U.S. next month.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","OMER":"奥麦罗制药"},"translate_title":"FDA批准Yartemlea后Omeros股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMER":1.5},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of Omeros surged after the pharmaceutical company received Food and Drug Administration approval for its Yartemlea treatment. \n\n\n  The stock was up 78% to $15.60 on Wednesday and was briefly paused for volatility. Shares have risen 56% this year. \n\n\n  The Seattle-based pharmaceutical company said Wednesday that the FDA greenlit Yartemlea for patients ages 2 and older who experience a serious complication from stem-cell transplant procedures. \n\n\n  The FDA approval makes Yartemlea the only approved treatment that works by inhibiting the effector enzyme of the lectin pathway, Omeros said. It said it is finalizing preparations for a product launch in the U.S. next month. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 24, 2025 11:55 ET (16:55 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}